BioCryst Pharmaceuticals Inc. (BCRX)

4.96
NASDAQ : Health Technology
Prev Close 4.87
Day Low/High 4.88 / 5.25
52 Wk Low/High 3.95 / 9.25
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 98.43M
Market Cap 480.35M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Short Interest Jumps 11% For BCRX

Short Interest Jumps 11% For BCRX

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,191,695 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 12,007,211, an increase of 11.02% since 11/15/2017.

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Commit To Buy BioCryst Pharmaceuticals At $3, Earn 10.7% Using Options

Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.

BioCryst Pharmaceuticals Becomes Oversold (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of BCRX August 18th Options Trading

First Week of BCRX August 18th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the August 18th expiration.

Biotech Movers: BioCryst, Omeros, Radius Health

Biotech Movers: BioCryst, Omeros, Radius Health

BioCryst Pharmaceuticals, Omeros and Radius Health were among the were among the biotech stock movers in premarket trading on July 3.

TheStreet Quant Rating: D- (Sell)